QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
OTCMKTS:VYNT

Vyant Bio (VYNT) Stock Forecast, Price & News

$0.16
+0.01 (+6.67%)
(As of 09/21/2023 ET)
Compare
Today's Range
$0.16
▼
$0.17
50-Day Range
$0.15
▼
$0.28
52-Week Range
$0.14
▼
$3.15
Volume
15,701 shs
Average Volume
214,562 shs
Market Capitalization
$1.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort Interest

Vyant Bio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
3,025.0% Upside
$5.00 Price Target
Short Interest
Healthy
0.87% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

See Top Rated MarketRank™ Stocks Here

VYNT stock logo

About Vyant Bio (OTCMKTS:VYNT) Stock

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.

VYNT Price History

VYNT Stock News Headlines

September 20, 2023 | finance.yahoo.com
Vyant Bio Announces Adjournment of Special Meeting of Stockholders
August 21, 2023 | yahoo.com
Medicare patients took unnecessary genetic cancer tests in man’s $463M scheme, feds say
September 21, 2023 | Stansberry Research (Ad)
Are "The Magnificent Seven" the Next Sears?
The former retail giant’s sales once accounted for 1% of the U.S. economy. Now it’s nearly extinct. Will the same happen to big tech? Learn more here.
August 21, 2023 | washingtonpost.com
‘Asian glow’ from alcohol isn’t just a discomfort. It’s a severe warning.
August 18, 2023 | msn.com
Gene that vastly increases chance of breast cancer found by scientists
August 17, 2023 | msn.com
The dangerous gene that vastly increases your chance of breast cancer
August 9, 2023 | msn.com
AI Can Find Cancer’s Origin: Study
July 18, 2023 | benzinga.com
Genprex – FDA Grants Fast Track Approval For Promising New Cancer Gene Therapy
September 21, 2023 | Stansberry Research (Ad)
Are "The Magnificent Seven" the Next Sears?
The former retail giant’s sales once accounted for 1% of the U.S. economy. Now it’s nearly extinct. Will the same happen to big tech? Learn more here.
July 17, 2023 | bizjournals.com
Vyant Bio enters into deal to sells its microBrain assets for $2.25M
July 17, 2023 | finance.yahoo.com
AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX Assets
July 6, 2023 | msn.com
Gene editing helped crack a 100-year-old mystery about cancer
July 3, 2023 | msn.com
Certain genetic mutations linked to treatment-resistant breast cancer, new study discovers
July 3, 2023 | msn.com
Testing begins for Orkney cancer gene link
June 29, 2023 | usatoday.com
Are you truly at risk for prostate cancer? Adding genetics may give more accurate PSA tests
June 7, 2023 | msn.com
KHCC presents Cancer Genetics study in leading conference in US
June 6, 2023 | msn.com
DNA sequencing can lead to longer, better lives for cancer patients. But why do so few get it?
June 2, 2023 | msn.com
Endometrial Cancer Warning Signs: What to Look Out For
May 25, 2023 | msn.com
UCLA researchers say genetic mutation could be key to treating fatal brain tumors
May 18, 2023 | msn.com
Junk genes may hold keys to cancer cure, CWRU researchers find
May 16, 2023 | technews.tmcnet.com
New Study Shows CancerIQ Plus Point-of-Care Genetic Testing Improves Access to Precision Prevention
May 12, 2023 | proactiveinvestors.com
Vyant Bio to pursue listing on OTC Pink Open Market
May 12, 2023 | finance.yahoo.com
Vyant Bio Announces Last Day of Trading on Nasdaq and Filing of Form 15 for Voluntary Nasdaq Delisting and SEC Deregistration
May 12, 2023 | marketwatch.com
8-K: Vyant Bio, Inc.
May 8, 2023 | washingtonpost.com
Ask a Doctor: Which cancers can be detected through genetic testing?
May 8, 2023 | markets.businessinsider.com
Genome Insight Launches in the U.S. with Innovative Whole Genome Sequencing Approach that Offers Unprecedented, Actionable Insights in Cancer Care
May 4, 2023 | finance.yahoo.com
Vyant Bio Announces Filing of Form 25 for Voluntary Nasdaq Delisting and SEC Deregistration
See More Headlines
Receive VYNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter.

VYNT Company Calendar

Last Earnings
11/11/2021
Today
9/21/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:VYNT
CUSIP
N/A
CIK
1349929
Web
stemonix.com
Phone
(201) 479-1357
Fax
201-528-9201
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+3,126.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-22,690,000.00
Net Margins
-3,474.81%
Pretax Margin
-3,281.86%
Return on Equity
-151.82%
Return on Assets
-97.14%

Debt

Debt-to-Equity Ratio
0.04
Current Ratio
2.86
Quick Ratio
2.86

Sales & Book Value

Annual Sales
$670,000.00
Price / Sales
1.46
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.69 per share
Price / Book
0.09

Miscellaneous

Outstanding Shares
6,330,000
Free Float
5,724,000
Market Cap
$981,086.70
Optionable
Not Optionable
Beta
1.79
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Andrew D.C. LaFrence CPA (Age 60)
    CPA, Pres, CEO & CFO
    Comp: $407.4k
  • Mr. Yung-Ping Yeh M.B.A.Mr. Yung-Ping Yeh M.B.A. (Age 47)
    M.S., P.M.P., Co-Founder & Director
    Comp: $22.5k

Key Competitors

View All Competitors













VYNT Stock - Frequently Asked Questions

Should I buy or sell Vyant Bio stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vyant Bio in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VYNT shares.
View VYNT analyst ratings or view top-rated stocks.

What is Vyant Bio's stock price forecast for 2023?

2 brokers have issued 1 year target prices for Vyant Bio's shares. Their VYNT share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 3,126.0% from the stock's current price.
View analysts price targets for VYNT or view top-rated stocks among Wall Street analysts.

How have VYNT shares performed in 2023?

Vyant Bio's stock was trading at $0.7025 on January 1st, 2023. Since then, VYNT shares have decreased by 77.9% and is now trading at $0.1550.
View the best growth stocks for 2023 here.

When is Vyant Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our VYNT earnings forecast.

How were Vyant Bio's earnings last quarter?

Vyant Bio, Inc. (OTCMKTS:VYNT) posted its quarterly earnings results on Thursday, November, 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.75). The company earned $1.51 million during the quarter, compared to analysts' expectations of $2.19 million. Vyant Bio had a negative trailing twelve-month return on equity of 151.82% and a negative net margin of 3,474.81%. During the same quarter in the prior year, the firm earned ($2.90) earnings per share.

When did Vyant Bio's stock split?

Vyant Bio shares reverse split on Wednesday, November 2nd 2022. The 1-5 reverse split was announced on Wednesday, November 2nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 2nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What is Vyant Bio's stock symbol?

Vyant Bio trades on the OTCMKTS under the ticker symbol "VYNT."

How do I buy shares of Vyant Bio?

Shares of VYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vyant Bio's stock price today?

One share of VYNT stock can currently be purchased for approximately $0.15.

How much money does Vyant Bio make?

Vyant Bio (OTCMKTS:VYNT) has a market capitalization of $981,086.70 and generates $670,000.00 in revenue each year.

How can I contact Vyant Bio?

Vyant Bio's mailing address is 2370 State Route 70 Suite 310, Cherry Hill NJ, 08002. The official website for the company is stemonix.com. The company can be reached via phone at (201) 479-1357, via email at jzimmons@zimmonsic.com, or via fax at 201-528-9201.

This page (OTCMKTS:VYNT) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -